search
Back to results

SUNDYS: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial (SUNDYS)

Primary Purpose

Dystonia

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Deep brain stimulation
Sponsored by
Ruijin Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dystonia focused on measuring Deep brain stimulation, Subthalamic nucleus, Randomized controlled trial

Eligibility Criteria

14 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients must meet criteria for the diagnosis of isolated generalized or segmental dystonia, including idiopathic and inherited dystonia, as defined by the Phenomenology and Classification of Dystonia: A Consensus Update 2013;
  2. Patients will be ≥ 14 years old;
  3. The course of disease will be ≥ 3 years;
  4. Patients will have:

    1. Significant dystonia symptoms;
    2. Compromised life quality;
    3. Unsatisfactory response to oral treatment with anticholinergic agents antiepileptic agents, anti-dopamine agents, dopaminergic agents, or muscle relaxants;
    4. Unsatisfactory response to or contraindication for previous botulinum toxin treatment; and
    5. Ability to provide written informed consent.

Exclusion Criteria:

  1. Patients with a diagnosis or probable diagnosis of acquired, compound, and complex dystonia, as defined by the Phenomenology and Classification of Dystonia: A Consensus Update 2013;
  2. Previous brain surgery for dystonia;
  3. Patients with cognitive impairment (MMSE score <24) or moderate-severe depressive disorder (BDI>25);
  4. Patients with marked brain atrophy identified by magnetic resonance imaging (MRI) or computed tomography (CT);
  5. Patients with other medical or psychiatric comorbidities that could increase the surgical risk or interfere with completion of the trial;
  6. Patients with increased bleeding risk, or other factors contraindicating neurosurgery or general anesthesia;
  7. Patients unable to cooperate with the assessments during the follow-up.

Sites / Locations

  • Shanghai Ruijin HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

STN DBS stimulation group

Sham stimulation group

Arm Description

In the STN DBS stimulation group, patients will receive a continuous DBS stimulation for 3 months and the first default parameters applied will be monopolar setting (0.5 V under threshold that causes side effects, 135 Hz, 90 µs, at one of the two dorsal contacts). If the default parameters are found not suitable for an individual patient due to unexpected reasons, an alternative method will be applied (e.g., decreased voltage) to try to maintain full compliance with the scheduled study.

In the sham stimulation group, the programming will also start within 1 week after the surgery, but at each follow-up the DBS system will be turned off after the parameter is adjusted to the threshold that causes side effects without continuous stimulation. After the 3-month double-blind period the patients can choose to set on the DBS system again and receive regular continuous stimulation treatment.

Outcomes

Primary Outcome Measures

The change from baseline to 3 months after stimulation of Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) score
The scale consists of a movement and disability subscale with scores ranging from 0 to 120 and 0 to 30, respectively, higher scores indicating greater impairment.

Secondary Outcome Measures

Abnormal Involuntary Movement Scale (AIMS)
The AIMS is a 12-item clinician-rated scale to assess severity of dyskinesias. These items are rated on a five-point scale of severity from 0-4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Two of the 12 items refer to dental care.
36-item Short-Form General Health survey (SF-36)
SF-36 is a measure of health-related quality-of-life with a 36-item patient-reported questionnaire that covers eight health domains. Higher scores indicate a more favorable health state.
Beck Depression Inventory-II (BDI)
BDI contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms.
Beck Anxiety Inventory (BAI)
BAI contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe anxiety symptoms.
Montreal Cognitive Assessment (MoCA)
MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal. Lower scores indicate more disability.
Cambridge Neuropsychological Test Automated Battery (CANTAB)
A detailed computerized cognitive battery selected from CANTAB includes: Stockings of Cambridge (SOC) and Spatial working memory (SWM) for executive function; Motor screening task (MOT) and a five-choice series selection task for attention; Paired associates learning (PAL) and Pattern recognition memory (PRM) for memory.
The rate of response
The number of patients with ≥30% improvement in the movement score on the BFMDRS
The rate of adverse event (AE)
Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)
The scale consists of a movement and disability subscale with scores ranging from 0 to 120 and 0 to 30, respectively, higher scores indicating greater impairment.

Full Information

First Posted
November 19, 2020
Last Updated
April 3, 2021
Sponsor
Ruijin Hospital
Collaborators
Renmin Hospital of Wuhan University, Shanghai Tongji Hospital, Tongji University School of Medicine, Second Affiliated Hospital of Soochow University, West China Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04650958
Brief Title
SUNDYS: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial
Acronym
SUNDYS
Official Title
Subthalamic Nucleus Deep Brain Stimulation in Isolated Generalized or Segmental Dystonia: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
December 1, 2021 (Anticipated)
Study Completion Date
January 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ruijin Hospital
Collaborators
Renmin Hospital of Wuhan University, Shanghai Tongji Hospital, Tongji University School of Medicine, Second Affiliated Hospital of Soochow University, West China Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Dystonia is a group of movement disorders characterized by twisting, repetitive movements, or abnormal postures caused by involuntary muscle contractions and is characterized by a young age of onset and a high disability rate. Early intervention can reduce disability incidence, improve the patient's quality of life, and reduce the burden on families and society. Multiple international guidelines on dystonia have found deep brain stimulation (DBS) to be a safe and effective treatment for refractory dystonia. The globus pallidal internus (GPi) is the mostly widely used target for dystonia. However, there are limitations on the GPi DBS treatment, including slow onset of beneficial effects, poor improvement of axis symptoms, and potential stimulation-related side effects. Previous studies have described the highly successful use of subthalamic nucleus deep brain stimulation (STN DBS) in patients with refractory dystonia, suggesting that STN DBS is an effective and persisting alternative to pallidal deep brain stimulation. However, all STN DBS treated cases have been analyzed in open-label uncontrolled cohort studies, leading to limited data with a high level of evidence on the STN DBS in dystonia. Further, the investigators hypothesized STN has potentially more effectiveness when compared with GPi, and may be more power-saving and quick-acting. In this study, the investigators will organize a prospective randomized, double-blind, parallel-group, multicenter study comparing active versus sham stimulation in isolated segmental or generalized dystonia to evaluate the effectiveness and safety of STN DBS by measuring the impact on motor status, mental status, quality of life, the rate of response of the patients (the number of patients with ≥30% improvement in the movement score on the Burke-Fahn-Marsden Dystonia Rating Scale) and the rate of adverse events during the trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dystonia
Keywords
Deep brain stimulation, Subthalamic nucleus, Randomized controlled trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
In this study after having DBS leads implanted successfully, 38 patients will be randomly assigned to either the control or experimental group with a 1:1 allocation. The experimental group will receive continuous DBS stimulation for 3 months, while controls will have sham stimulation for 3 months.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The randomization will be conducted by the Coordination Center of Clinical Trials (CenTrial) in order to keep the researchers managing the data and the statistician blind to group assignment and the study conditions. All the clinical assessments done during the trial period will be double-blind, e.g., neither the patient not the clinician or study personnel involved in the scoring will not be aware of the condition of stimulation. All personnel, except the physician-programmer responsible for the DBS setting, will be blinded to the identity of the parameters. While programming the programmer will not sit face-to-face with the patient, but in another room adjusting the parameter wirelessly with the help of the attending doctor who will inform the programmer of the patient's reaction. The electrical parameters will be tested in all patients which means they all will perceive similar stimulation related sensations during each follow-up.
Allocation
Randomized
Enrollment
38 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
STN DBS stimulation group
Arm Type
Active Comparator
Arm Description
In the STN DBS stimulation group, patients will receive a continuous DBS stimulation for 3 months and the first default parameters applied will be monopolar setting (0.5 V under threshold that causes side effects, 135 Hz, 90 µs, at one of the two dorsal contacts). If the default parameters are found not suitable for an individual patient due to unexpected reasons, an alternative method will be applied (e.g., decreased voltage) to try to maintain full compliance with the scheduled study.
Arm Title
Sham stimulation group
Arm Type
Sham Comparator
Arm Description
In the sham stimulation group, the programming will also start within 1 week after the surgery, but at each follow-up the DBS system will be turned off after the parameter is adjusted to the threshold that causes side effects without continuous stimulation. After the 3-month double-blind period the patients can choose to set on the DBS system again and receive regular continuous stimulation treatment.
Intervention Type
Procedure
Intervention Name(s)
Deep brain stimulation
Intervention Description
Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
Primary Outcome Measure Information:
Title
The change from baseline to 3 months after stimulation of Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) score
Description
The scale consists of a movement and disability subscale with scores ranging from 0 to 120 and 0 to 30, respectively, higher scores indicating greater impairment.
Time Frame
Baseline; 3months after stimulation
Secondary Outcome Measure Information:
Title
Abnormal Involuntary Movement Scale (AIMS)
Description
The AIMS is a 12-item clinician-rated scale to assess severity of dyskinesias. These items are rated on a five-point scale of severity from 0-4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Two of the 12 items refer to dental care.
Time Frame
Baseline; 1 week, 1 month and 3months after stimulation
Title
36-item Short-Form General Health survey (SF-36)
Description
SF-36 is a measure of health-related quality-of-life with a 36-item patient-reported questionnaire that covers eight health domains. Higher scores indicate a more favorable health state.
Time Frame
Baseline; 1 week, 1 month and 3months after stimulation
Title
Beck Depression Inventory-II (BDI)
Description
BDI contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms.
Time Frame
Baseline; 1 week, 1 month and 3months after stimulation
Title
Beck Anxiety Inventory (BAI)
Description
BAI contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe anxiety symptoms.
Time Frame
Baseline; 1 week, 1 month and 3months after stimulation
Title
Montreal Cognitive Assessment (MoCA)
Description
MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal. Lower scores indicate more disability.
Time Frame
Baseline; 3months after stimulation
Title
Cambridge Neuropsychological Test Automated Battery (CANTAB)
Description
A detailed computerized cognitive battery selected from CANTAB includes: Stockings of Cambridge (SOC) and Spatial working memory (SWM) for executive function; Motor screening task (MOT) and a five-choice series selection task for attention; Paired associates learning (PAL) and Pattern recognition memory (PRM) for memory.
Time Frame
Baseline; 3months after stimulation
Title
The rate of response
Description
The number of patients with ≥30% improvement in the movement score on the BFMDRS
Time Frame
1 week, 1 month and 3months after stimulation
Title
The rate of adverse event (AE)
Time Frame
Within 1 week after surgery; 1 week, 1 month and 3months after stimulation
Title
Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)
Description
The scale consists of a movement and disability subscale with scores ranging from 0 to 120 and 0 to 30, respectively, higher scores indicating greater impairment.
Time Frame
1 week and 1 month after stimulation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must meet criteria for the diagnosis of isolated generalized or segmental dystonia, including idiopathic and inherited dystonia, as defined by the Phenomenology and Classification of Dystonia: A Consensus Update 2013; Patients will be ≥ 14 years old; The course of disease will be ≥ 3 years; Patients will have: Significant dystonia symptoms; Compromised life quality; Unsatisfactory response to oral treatment with anticholinergic agents antiepileptic agents, anti-dopamine agents, dopaminergic agents, or muscle relaxants; Unsatisfactory response to or contraindication for previous botulinum toxin treatment; and Ability to provide written informed consent. Exclusion Criteria: Patients with a diagnosis or probable diagnosis of acquired, compound, and complex dystonia, as defined by the Phenomenology and Classification of Dystonia: A Consensus Update 2013; Previous brain surgery for dystonia; Patients with cognitive impairment (MMSE score <24) or moderate-severe depressive disorder (BDI>25); Patients with marked brain atrophy identified by magnetic resonance imaging (MRI) or computed tomography (CT); Patients with other medical or psychiatric comorbidities that could increase the surgical risk or interfere with completion of the trial; Patients with increased bleeding risk, or other factors contraindicating neurosurgery or general anesthesia; Patients unable to cooperate with the assessments during the follow-up.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kejia Hu, MD, PhD
Phone
18930113801
Email
dockejiahu@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bomin Sun
Organizational Affiliation
Ruijin Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shanghai Ruijin Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kejia Hu, MD,PhD
Phone
+86 18930113801
Email
dockejiahu@gmail.com

12. IPD Sharing Statement

Learn more about this trial

SUNDYS: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial

We'll reach out to this number within 24 hrs